Search Results - "TALAN, MARK I"

Effects of calorie restriction on cardioprotection and cardiovascular health by Ahmet, Ismayil, Tae, Hyun-Jin, de Cabo, Rafael, Lakatta, Edward G, Talan, Mark I

“…Abstract Multiple health benefits of calorie restriction (CR) and alternate day fasting (ADF) regimens are widely recognized. Experimental data concerning the…”
Get full text

β2 AR Agonists in Treatment of Chronic Heart Failure: Long Path to Translation by Talan, Mark I, Ahmet, Ismayil, Xiao, Riu-Ping, Lakatta, Edward G

“…Abstract The main clinical manifestations of advanced chronic heart failure (CHF), e.g. in dilated cardiomyopathy (DCM), are reduced systolic and diastolic…”
Get full text

Erythropoietin Reduces Myocardial Infarction and Left Ventricular Functional Decline after Coronary Artery Ligation in Rats by Moon, Chanil, Krawczyk, Melissa, Ahn, Dongchoon, Ahmet, Ismayil, Paik, Doojin, Lakatta, Edward G., Talan, Mark I.

“…Erythropoietin (EPO), well known for its role in stimulation of erythropoiesis, has recently been shown to have a dramatic neuroprotective effect in animal…”
Get full text

Chronic administration of small nonerythropoietic peptide sequence of erythropoietin effectively ameliorates the progression of postmyocardial infarction-dilated cardiomyopathy by Ahmet, Ismayil, Tae, Hyun-Jin, Brines, Michael, Cerami, Anthony, Lakatta, Edward G, Talan, Mark I

“…The cardioprotective properties of erythropoietin (EPO) in preclinical studies are well documented, but erythropoietic and prothrombotic properties of EPO…”
Get more information

Did clinical trials in which erythropoietin failed to reduce acute myocardial infarct size miss a narrow therapeutic window? by Talan, Mark I, Ahmet, Ismayil, Lakatta, Edward G

“…To test a hypothesis that in negative clinical trials of erythropoietin in patients with acute myocardial infarction (MI) the erythropoietin (rhEPO) could be…”
Get full text

A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage by Ahmet, Ismayil, Tae, Hyun-Jin, Juhaszova, Magdalena, Riordon, Daniel R, Boheler, Kenneth R, Sollott, Steven J, Brines, Michael, Cerami, Anthony, Lakatta, Edward G, Talan, Mark I

“…Strong cardioprotective properties of erythropoietin (EPO) reported over the last 10 years have been difficult to translate to clinical applications for…”
Get full text

Allele‐specific siRNA knockdown as a personalized treatment strategy for vascular Ehlers‐Danlos syndrome in human fibroblasts by Müller, Gerd A., Hansen, Uwe, Xu, Zhi, Griswold, Benjamin, Talan, Mark I., McDonnell, Nazli B., Briest, Wilfried

“…ABSTRACT The vascular type of the Ehlers‐Danlos syndrome (vEDS) is caused by dominant‐negative mutations in the procollagen type III (COL3A1) gene. Patients…”
Get full text

Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties by Moon, Chanil, Krawczyk, Melissa, Paik, Doojin, Coleman, Thomas, Brines, Michael, Juhaszova, Magdalena, Sollott, Steven J, Lakatta, Edward G, Talan, Mark I

“…Erythropoietin (EPO), a hematopoietic cytokine, possesses strong antiapoptotic, tissue-protective properties. For clinical applications, it is desirable to…”
Get more information

Doxycycline ameliorates the susceptibility to aortic lesions in a mouse model for the vascular type of Ehlers-Danlos syndrome by Briest, Wilfried, Cooper, Timothy K, Tae, Hyun-Jin, Krawczyk, Melissa, McDonnell, Nazli B, Talan, Mark I

“…The vascular form of Ehlers-Danlos syndrome (vEDS), a rare disease with grave complications resulting from rupture of major arteries, is caused by mutations of…”
Get more information

Chronic Alternate-Day Fasting Results in Reduced Diastolic Compliance and Diminished Systolic Reserve in Rats by Ahmet, Ismayil, MD, PhD, Wan, Ruiqian, PhD, Mattson, Mark P., PhD, Lakatta, Edward G., MD, Talan, Mark I., MD, PhD

“…Abstract Background Based on animal experiments and limited data from the few human trials, alternate-day fasting (ADF) resulted in weight loss, prolonged…”
Get full text

Induction of myocardial infarcts of a predictable size and location by branch pattern probability-assisted coronary ligation in C57BL/6 mice by Ahn, Dongchoon, Cheng, Linda, Moon, Chanil, Spurgeon, Harold, Lakatta, Edward G, Talan, Mark I

“…The ability to create experimental myocardial infarctions of reproducible size and location is tantamount to progress in multiple facets of ischemic heart…”
Get more information

Vessel Ultrasound Sonographic Assessment of Soluble Receptor for Advanced Glycation End Products Efficacy in a Rat Balloon Injury Model by Tae, Hyun-Jin, DVM, PhD, Petrashevskaya, Natalia, PhD, Ahmet, Ismayil, PhD, Park, Sungha, MD, PhD, Talan, Mark I., MD, PhD, Lakatta, Edward G., MD, Lin, Li, PhD

“…Abstract Objective We aimed to assess the therapeutic efficacy of differentially modified soluble receptor for advanced glycation end products (sRAGE) in vivo…”
Get full text

Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction : Dose response and therapeutic window by MOON, Chanil, KRAWCZYK, Melissa, PAIK, Doojin, LAKATTA, Edward G, TALAN, Mark I

“…Recombinant human erythropoietin (rhEPO) protects tissue from ischemic damage, but translation of this finding into useful guidelines with respect to human…”
Get full text

SRT1720 improves survival and healthspan of obese mice by Minor, Robin K., Baur, Joseph A., Gomes, Ana P., Ward, Theresa M., Csiszar, Anna, Mercken, Evi M., Abdelmohsen, Kotb, Shin, Yu-Kyong, Canto, Carles, Scheibye-Knudsen, Morten, Krawczyk, Melissa, Irusta, Pablo M., Martín-Montalvo, Alejandro, Hubbard, Basil P., Zhang, Yongqing, Lehrmann, Elin, White, Alexa A., Price, Nathan L., Swindell, William R., Pearson, Kevin J., Becker, Kevin G., Bohr, Vilhelm A., Gorospe, Myriam, Egan, Josephine M., Talan, Mark I., Auwerx, Johan, Westphal, Christoph H., Ellis, James L., Ungvari, Zoltan, Vlasuk, George P., Elliott, Peter J., Sinclair, David A., de Cabo, Rafael

“…Sirt1 is an NAD + -dependent deacetylase that extends lifespan in lower organisms and improves metabolism and delays the onset of age-related diseases in…”
Get full text

Acute hemodynamic effects of erythropoietin do not mediate its cardioprotective properties by Ahmet, Ismayil, Lakatta, Edward G, Talan, Mark I

“…Activation of nitric oxide (NO) signaling is considered, at list partially, a mechanistic basis for EPO-induced cardioprotection. Surprisingly, hemodynamic…”
Get full text

Myocardial infarction: cardioprotection by erythropoietin by Talan, Mark I, Latini, Roberto

“…Extensive research during the last decade demonstrated that a single systemic administration of -erythropoietin (EPO) lead to significant attenuation of…”
Get more information

Chronic treatment with a broad-spectrum metalloproteinase inhibitor, doxycycline, prevents the development of spontaneous aortic lesions in a mouse model of vascular Ehlers-Danlos syndrome by Tae, Hyun-Jin, Marshall, Shannon, Zhang, Jing, Wang, Mingyi, Briest, Wilfried, Talan, Mark I

“…There is no proven therapy or prevention for vascular Ehlers-Danlos syndrome (vEDS), a genetic disorder associated with the mutation of procollagen type III…”
Get more information

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics by Petrasheskaya, Natalia, Tae, Hyun-Jin, Ahmet, Ismayil, Talan, Mark I, Lakatta, Edward G, Lin, Li

“…The rat carotid balloon injury is a well-established surgical model that has been used to study arterial remodeling and vascular cell proliferation. It is also…”
Get full text

Beneficial effects of chronic pharmacological manipulation of β-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy by AHMET, Ismayil, KRAWCZYK, Melissa, HELLER, Phillip, MOON, Chanil, LAKATTA, Edward G, TALAN, Mark I

“…Studies in isolated cardiac myocytes have demonstrated that signaling via specific beta1-adrenergic receptor subtypes (beta1ARs) promotes but that signaling…”
Get full text

The N-glycoform of sRAGE is the key determinant for its therapeutic efficacy to attenuate injury-elicited arterial inflammation and neointimal growth by Tae, Hyun-Jin, Kim, Ji Min, Park, Sungha, Tomiya, Noboru, Li, Geng, Wei, Wen, Petrashevskaya, Natalia, Ahmet, Ismayil, Pang, John, Cruschwitz, Stefanie, Riebe, Rebecca A., Zhang, Yinghua, Morrell, Christopher H., Browe, David, Lee, Yuan Chuan, Xiao, Rui-ping, Talan, Mark I., Lakatta, Edward G., Lin, Li

“…Signaling of the receptor for advanced glycation end products (RAGE) has been implicated in the development of injury-elicited vascular complications. Soluble…”
Get full text